Circulating tumour DNA sequencing reveal mechanisms of resistance to BRAF-targeted therapies in BRAF-mutated gastrointestinal stromal tumour

Jones et al. published in a recent issue of the European Journal of Cancer a seminal study describing the long-term efficacy results of new generation tyrosine kinase inhibitor, avapritinib, in a rare subtype of gastrointestinal stromal tumor (GIST), namely PDGFRα D842V-mutant GIST which is primary resistant to imatinib [1].